Literature DB >> 18242501

Cholangiocarcinoma.

Boris R A Blechacz1, Gregory J Gores.   

Abstract

Cholangiocarcinoma is a primary hepatic malignancy originating from bile duct epithelium. It is the second most common primary hepatic neoplasia, and its incidence has increased within the last 3 decades. Although several risk factors have been identified, especially chronic biliary tract inflammation, most patients with cholangiocarcinoma have no identifiable risk factors. Recent developments in radiologic and molecular diagnostic methods have helped in the diagnosis of this disease. The only curative therapy is surgical resection or liver transplantation. For patients with advanced stage disease, survival remains limited. With growing understanding of the molecular and cellular etiology of this disease, new targeted therapies are being developed.

Entities:  

Mesh:

Year:  2008        PMID: 18242501     DOI: 10.1016/j.cld.2007.11.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  101 in total

1.  Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma.

Authors:  Marcin Krawczyk; Florentina Mihalache; Aksana Höblinger; Monica Acalovschi; Frank Lammert; Vincent Zimmer
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

Review 3.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

4.  Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.

Authors:  Yu Jin Lim; Jaemoon Koh; Kyubo Kim; Eui Kyu Chie; Sehui Kim; Kyoung Bun Lee; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

5.  Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.

Authors:  Martha M Kirstein; Steffen Marquardt; Nils Jedicke; Silke Marhenke; Wolfgang Koppert; Michael P Manns; Frank Wacker; Arndt Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-20       Impact factor: 4.553

6.  Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.

Authors:  Ting Liu; Heping Yang; Wei Fan; Jian Tu; Tony W H Li; Jiaohong Wang; Hong Shen; JinWon Yang; Ting Xiong; Justin Steggerda; Zhenqiu Liu; Mazen Noureddin; Stephanie S Maldonado; Alagappan Annamalai; Ekihiro Seki; José M Mato; Shelly C Lu
Journal:  Gastroenterology       Date:  2018-05-05       Impact factor: 22.682

7.  Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.

Authors:  Kawin Leelawat; Siriluck Narong; Jerasak Wannaprasert; Thawee Ratanashu-ek
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 8.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

9.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.

Authors:  Giammarco Fava; Sharon Demorrow; Eugenio Gaudio; Antonio Franchitto; Paolo Onori; Guido Carpino; Shannon Glaser; Heather Francis; Monique Coufal; Luca Marucci; Domenico Alvaro; Marco Marzioni; Trenton Horst; Romina Mancinelli; Antonio Benedetti; Gianfranco Alpini
Journal:  Liver Int       Date:  2009-03-09       Impact factor: 5.828

10.  BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.

Authors:  Humaid O Al-Shamsi; Deepa Anand; Rachna T Shroff; Apurva Jain; Mingxin Zuo; Claudius Conrad; Jean-Nicolas Vauthey; Milind M Javle
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.